Rhythm Income Tax Expense from 2010 to 2024

RYTM Stock  USD 56.12  0.64  1.15%   
Rhythm Pharmaceuticals Income Tax Expense yearly trend continues to be very stable with very little volatility. Income Tax Expense is likely to grow to about 592.2 K this year. During the period from 2010 to 2024, Rhythm Pharmaceuticals Income Tax Expense quarterly data regression pattern had sample variance of 5.3 T and median of 0.00. View All Fundamentals
 
Income Tax Expense  
First Reported
2013-12-31
Previous Quarter
479 K
Current Value
-344 K
Quarterly Volatility
4.4 M
 
Yuan Drop
 
Covid
Check Rhythm Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Rhythm Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.8 M, Interest Expense of 11 M or Selling General Administrative of 117 M, as well as many indicators such as Price To Sales Ratio of 32.53, Dividend Yield of 0.0 or PTB Ratio of 16.4. Rhythm financial statements analysis is a perfect complement when working with Rhythm Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Rhythm Pharmaceuticals Correlation against competitors.
To learn how to invest in Rhythm Stock, please use our How to Invest in Rhythm Pharmaceuticals guide.

Latest Rhythm Pharmaceuticals' Income Tax Expense Growth Pattern

Below is the plot of the Income Tax Expense of Rhythm Pharmaceuticals over the last few years. It is Rhythm Pharmaceuticals' Income Tax Expense historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Rhythm Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Income Tax Expense10 Years Trend
Very volatile
   Income Tax Expense   
       Timeline  

Rhythm Income Tax Expense Regression Statistics

Arithmetic Mean(162,253)
Geometric Mean0.00
Coefficient Of Variation(1,424)
Mean Deviation1,398,965
Median0.00
Standard Deviation2,310,826
Sample Variance5.3T
Range10.5M
R-Value(0.05)
Mean Square Error5.7T
R-Squared0
Significance0.87
Slope(24,088)
Total Sum of Squares74.8T

Rhythm Income Tax Expense History

2024592.2 K
2023564 K
2022M
2021-1.6 M
2020-3.3 M
2019-6.1 M
20184.4 M

About Rhythm Pharmaceuticals Financial Statements

Rhythm Pharmaceuticals investors utilize fundamental indicators, such as Income Tax Expense, to predict how Rhythm Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Income Tax Expense564 K592.2 K

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Rhythm Pharmaceuticals is a strong investment it is important to analyze Rhythm Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Rhythm Pharmaceuticals' future performance. For an informed investment choice regarding Rhythm Stock, refer to the following important reports:
Check out the analysis of Rhythm Pharmaceuticals Correlation against competitors.
To learn how to invest in Rhythm Stock, please use our How to Invest in Rhythm Pharmaceuticals guide.
You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rhythm Pharmaceuticals. If investors know Rhythm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rhythm Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(4.32)
Revenue Per Share
1.863
Quarterly Revenue Growth
0.478
Return On Assets
(0.46)
Return On Equity
(1.48)
The market value of Rhythm Pharmaceuticals is measured differently than its book value, which is the value of Rhythm that is recorded on the company's balance sheet. Investors also form their own opinion of Rhythm Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Rhythm Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rhythm Pharmaceuticals' market value can be influenced by many factors that don't directly affect Rhythm Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rhythm Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Rhythm Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rhythm Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.